Author

Wen-Bin Qian

h-index 19 View on Semantic Scholar

We have 3 of 123 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Zanubrutinib monotherapy in CD79B‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study

Diffuse large B ‐ cell lymphoma (DLBCL) remains a clinically and molecularly heterogeneous disease, 1 with approximately one ‐ third of patients developing relapsed or refractory (R/R) disease following frontline immunochemotherapy. 2,3 Among molecularly defined sub-groups, CD79B mutations occur in 5% – 25% of DLBCL

Li Wang, K. Zhou, Fei Li et al. · HemaSphere · 0 citations

Sep 2026

EphA2 Silencing Attenuates IL-1β-Induced Chondrocyte Ferroptosis and Extracellular Matrix Degradation In Vitro.

EphA2 silencing attenuates IL-1β-induced chondrocyte injury, ECM dysregulation, and ferroptosis-associated alterations in vitro and may contribute to ferroptosis-associated chondrocyte dysfunction in OA, warranting further mechanistic and in vivo studies.

Yan Chen, Wen-Bin Qian, Hu-Die Zhu · Cell Biochemistry and Biophy... · 0 citations

Jul 2026

Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.

Third-generation anti-CD30 CAR T-cell therapy demonstrates high efficacy and a favorable safety profile in r/r CD30+ lymphoma patients and addition of auto-HSCT following CAR T-cell therapy improves depth of remission and potentially enhances OS and PFS.

Xiang-Min Wang, Qing Zhang, Dong-Mei Yan et al. · Clinical Cancer Research · 0 citations